

MMRF FastFacts

A monthly e-newsletter



Dear Friends:

We are extremely proud to see incredible progress from our four-year Multiple Myeloma Research Consortium (MMRC) collaboration with Onyx (previously



Proteolix), as recently released Phase IIb trial results showed an incredible 36 percent of heavily pre-treated multiple myeloma patients demonstrated at least a minor response to treatment with carfilzomib. The MMRC accrued the majority — 60 percent — of patients into the trial, while representing just over one-third of the sites. This confirms our important role in managing 25 clinical trials to accelerate the development and availability of new treatments for multiple myeloma. Read more about the news on my [blog](#).

Warmest regards,

Kathy Giusti

Founder and CEO

P.S. We value your feedback – [please let us know what you think](#).

BREAKING NEWS

MMRC Helps to Advance Clinical Development of Carfilzomib

Positive data from the pivotal Phase IIb clinical trial (003-A1) of Onyx Pharmaceutical's carfilzomib in relapsed and refractory multiple myeloma, one of 25 clinical trials conducted entirely or in

CLINICAL TRIALS

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

[More >](#)

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

[More >](#)

Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

[More >](#)

EXPERT INSIGHTS

Dr. Kenneth Anderson of the Dana-Farber Cancer Institute, and Dr. Philip Greipp of the Mayo Clinic share their viewpoints on maintenance therapy after high-dose chemotherapy and stem cell

part through the MMRC, may provide the foundation for Onyx to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) by year-end, for potential accelerated approval. The 003-A1 trial was conducted through the MMRC as part of its commitment to accelerating the development of next-generation treatments for multiple myeloma, an incurable blood cancer. [More >](#)

[Click here to view the Onyx Press Release.](#)

Share: [in](#) [f](#) [t](#) [✉](#)

MMRF Welcomes Walter Capone as COO

The MMRF is pleased to welcome Walter Capone as Chief Operating Officer. Walter, who has more than 20 years of experience within the pharmaceutical industry, most recently served as Vice President of Commercial Development and Operations at Progenics Pharmaceuticals. He will serve on the MMRF Executive Committee and will report directly to MMRF Founder and CEO Kathy Giusti. [More >](#)

Share: [in](#) [f](#) [t](#) [✉](#)

Mount Sinai School of Medicine Joins MMRC

Mount Sinai has become the newest Member Institution to join the MMRC to accelerate the development of new treatments for multiple myeloma. [More >](#)

Share: [in](#) [f](#) [t](#) [✉](#)

RESEARCH UPDATES

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) [More >](#)

Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa AM, Hulin C, Facon T, Attal M, Minvielle S, Harousseau JL. *J Clin Oncol.* 2010 Jul 19. [Epub ahead of print]

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone [More >](#)

transplant.

[LEARN MORE](#)

Share: [in](#) [f](#) [t](#) [✉](#)

MMRF CLINICAL INSIGHTS

Learn about myeloma treatment options. Join us at our upcoming patient education programs on Wed. Sept. 8, in St. Louis, and Fri. Oct. 15, in Houston. For more information, email [Sara Tyghter](#) or call 203.652.0219.

[REGISTER NOW](#)

Share: [in](#) [f](#) [t](#) [✉](#)

GET INVOLVED

MMRF Fall Gala

Register now! The 14th Annual MMRF Fall Gala will be held Sat., Oct. 30, at the Hyatt Regency in Greenwich, Conn. Famed Pianist and Vocalist Diana Krall will perform as the event's featured artist and will be joined by legendary singer and songwriter Paul Simon. Deborah Norville, Emmy Award-winning broadcast journalist, will serve as mistress of ceremonies. For more information, email mmrf@benefitoffice.org.

[PURCHASE TICKETS](#)

Share: [in](#) [f](#) [t](#) [✉](#)

Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, Komarnicki M, Mateos MV, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF. *Blood*. 2010 Jul 13. [Epub ahead of print]

[Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment](#) [More >](#)

Dimopoulos MA, Christoulas D, Roussou M, Kastiris E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E. *Eur J Haematol*. 2010 Jul;85(1):1-5.

[Melfhalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.](#) [More >](#)

Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P; Italian Multiple Myeloma Network GIMEMA. *Haematologica*. 2010 Jul;95(7):1144-9.

[Phase III study of the value of thalidomide added to melfhalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study](#) [More >](#)

Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst H, Sonneveld P; Dutch-Belgium Cooperative Group HOVON. *J Clin Oncol*. 2010 Jul 1;28(19):3160-6.

[Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study](#) [More >](#)

Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV. *Leukemia*. 2010 Jul;24(7):1350-6.

MMRF Race for Research Fall Races

Registration is open for the MMRF Race for Research: 5K Walk/Run events taking place this Fall in Boston, Chicago, Philadelphia, Washington D.C. and the Twin Cities! Register today & start your fundraising now! For more information, email aces@themmrf.org.

[REGISTER NOW](#)

Share: [in](#) [f](#) [t](#) [✉](#)

Start a Fundraiser

Swing for a Cure at the [Alexander R. Rich, Jr. Multiple Myeloma Charity Golf Tournament](#). For more information about [Additional Golf Tournaments](#), or starting your own event, contact [Alex Karnell](#).

[REGISTER NOW](#)

Share: [in](#) [f](#) [t](#) [✉](#)

MMRF Store

Purchase apparel or jewelry from the MMRF as a gift to say thank you, or to recognize a special occasion, and support our mission in style.

[SHOP NOW!](#)

Share: [in](#) [f](#) [t](#) [✉](#)

Multiple Myeloma Research Foundation • 203.229.0464 • info@themmrf.org
383 Main Avenue, 5th Floor, Norwalk, CT 06851

Replies to this email cannot be read, please contact info@themmrf.org.

You are subscribed as . [Unsubscribe](#) to no longer receive breaking news and announcements from the MMRF.